Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

Unicycive Therapeutics (Nasdaq: UNCY) will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026. Chief Executive Officer Shalabh Gupta, M.D., will present at 2:30 p.m. ET. A live and archived webcast will be available through the Events and Presentations page in the Investors section of the company website.

Key Terms

hyperphosphatemia, delayed graft function, orphan drug designation, dose-ranging

4 terms

hyperphosphatemia medical

"for the treatment of hyperphosphatemia in patients with chronic kidney disease"

An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.

delayed graft function medical

"for the prevention of Delayed Graft Function (DGF) in kidney transplant patients"

Delayed graft function is when a transplanted organ—most commonly a kidney—does not start working right away after surgery, usually identified by the need for dialysis within the first week or by very low urine output. It matters to investors because it is a common clinical outcome used to measure transplant success, influences short-term hospital costs, patient recovery time, and can affect longer-term graft survival and regulatory or trial results.

orphan drug designation regulatory

"It has been granted orphan drug designation (ODD) by the FDA"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

dose-ranging medical

"completed a Phase 1 dose-ranging safety study in healthy volunteers"

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:

Unicycive Therapeutics
media@unicycive.com

SOURCE: Unicycive Therapeutics, Inc.